Interestingly such statin agents possess increasingly recognised pleiotropic effects beyond that of cholesterol lowering, including CTGF inhibition, preventing myofibroblast formation and anti-fibrotic effects in kidney disease and heart disease [26,27]. Here, CCN2 is linked to heart disorder.